kabutan

Kyowa Kirin Co., Ltd.(4151) Summary

4151
TSE Prime
Kyowa Kirin Co., Ltd.
2,553.5
JPY
+26.0
(+1.03%)
Dec 12, 3:30 pm JST
16.39
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
23.4
PBR
1.58
Yield
2.35%
Margin Trading Ratio
33.62
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
2,540.0 JPY 16.33 USD
Previous Close Dec 11
2,527.5 JPY 16.19 USD
High Dec 12, 9:01 am
2,565.0 JPY 16.49 USD
Low Dec 12, 9:24 am
2,519.0 JPY 16.18 USD
Volume
1,227,500
Trading Value
3.12B JPY 0.02B USD
VWAP
2543.37 JPY 16.32 USD
Minimum Trading Value
255,350 JPY 1,639 USD
Market Cap
1.34T JPY 8.66B USD
Number of Trades
3,151
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
High
1-Year Average
2,796
1-Year High May 2, 2025
11,280
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 53,400 178,500 3.34
Nov 28, 2025 49,700 197,400 3.97
Nov 21, 2025 89,900 210,600 2.34
Nov 14, 2025 38,600 139,000 3.60
Nov 7, 2025 31,800 177,500 5.58
Company Profile
Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Group, focusing on pharmaceutical business and new drug development through its biotechnology division. The company has formed a partnership with Fujifilm.
Sector
Pharmaceuticals
Kyowa Kirin Co., Ltd. primarily engages in the manufacture and sale of prescription pharmaceuticals. The company has numerous subsidiaries and equity-method affiliates, with Kirin Holdings as its parent company. Kyowa Kirin operates globally, with a particular focus on four key markets: Japan, North America, Europe, and Asia-Oceania. The company excels in biopharmaceutical development, possessing a unique drug discovery platform centered on antibody drug development and manufacturing technologies. Kyowa Kirin concentrates on creating new drugs that address unmet medical needs, particularly in disease areas such as nephrology, oncology, and immunology-allergy.